J Cancer 2011; 2:324-328. doi:10.7150/jca.2.324

Short Report

Targeting EGFR in Triple Negative Breast Cancer

Naoto T. Ueno1,2, Dongwei Zhang1,2 ✉

1. Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;
2. Department of Breast Medical Oncology, Morgan Welch Inflammatory Breast Cancer Research Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abstract

Our preliminary data show that erlotinib inhibits Triple-negative breast cancer (TNBC) in a xenograft model. However, inhibition of metastasis by erlotinib is accompanied by nonspecific effects because erlotinib can inhibit other kinases; thus, more direct targets that regulate TNBC metastasis need to be identified to improve its therapeutic efficacy.

Keywords: triple negative breast cancer, tyrosine kinase inhibitor, EGFR, erlotinib, metastasis

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Ueno NT, Zhang D. Targeting EGFR in Triple Negative Breast Cancer. J Cancer 2011; 2:324-328. doi:10.7150/jca.2.324. Available from http://www.jcancer.org/v02p0324.htm